Radiopharmaceuticals for diagnosis and treatment. Progress report [electronic resource].
- Washington, D.C. : United States. Dept. of Energy, 1992.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
- Physical Description:
- 6 pages : digital, PDF file
- Additional Creators:
- University of Michigan. Medical Center. Division of Nuclear Medicine
United States. Department of Energy
United States. Department of Energy. Office of Scientific and Technical Information
- We report on our efforts in PET basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. These efforts are focused on three fronts. First predictive abilities in nucleophilic aromatic substitution with [¹⁸F]fluorination of substituted aromatic rings. Although radiochemical yields can be predicted within a very similar group of compounds with similar leaving groups and substituent patterns, generalization to all nucleophilic substitutions with [¹⁸F] fluoride is not warranted. Kinetic studies indicate significantly different rates of reactions, depending on ring substituents. Second, preclinical evaluation of new radiopharmaceuticals. We have synthesized and begun the preclinical evaluation of [¹¹C]tetrabenazine, a new radioligand based on the vesicular monoamine transport system. Third, our work, on [¹⁸F]fluorination/decarbonylation reactions, structure-activity relationships in dopamine uptake inhibitors and effects of chronic drugs on radioligand binding is described.
- Published through SciTech Connect.
- Type of Report and Period Covered Note:
- Annual; 12/31/1992 - 12/31/1992
- Funding Information:
View MARC record | catkey: 14760453